

RHEUMAVISION 2026
CALL FOR ABSTRACT SUBMISSION

1. Scope of Abstracts:

Abstracts are invited in the following areas related to Rheumatology and Musculoskeletal (MSK) Health:		
<p><u>Original Research</u></p> <ul style="list-style-type: none"> • Autoimmune rheumatic diseases • Inflammatory arthritis (RA, SpA, PsA) • Connective tissue diseases • Vasculitis & overlap syndromes • Osteoporosis & metabolic bone diseases • MSK imaging & diagnostics • Rheumatology epidemiology & outcomes research 	<p><u>Case Reports / Case Series</u></p> <ul style="list-style-type: none"> • Rare or unusual rheumatic diseases • Challenging or atypical presentations • Novel diagnostic approaches • Treatment dilemmas or unique management strategies • Important learning points for clinical practice 	<p><u>Allied s Multidisciplinary Topics</u></p> <ul style="list-style-type: none"> • Rheumatology nursing & allied health • Rehabilitation & physiotherapy • Laboratory diagnostics in rheumatology • Quality improvement & audit in rheumatology care

2. Abstract Submission Guidelines:

<p><u>Abstract Structure</u></p> <ul style="list-style-type: none"> • Title (Sentence case, no abbreviations) • Authors s Affiliations • Background • Objectives • Methods • Results • Conclusion <p><i>(For Case Reports: Background - Case Description - Discussion - Conclusion)</i></p>
<p><u>Word Limit</u></p> <ul style="list-style-type: none"> • Maximum 300 words (excluding title and authors)
<p><u>Language</u></p> <ul style="list-style-type: none"> • Abstracts must be submitted in English

3. Poster Format Guidelines

<p><u>Poster Size</u> A0 size (Portrait orientation only) Dimensions: 840 mm × 1190 mm</p>	<p><u>Required Sections on Poster</u></p> <ul style="list-style-type: none"> • Title & Authors • Introduction / Background • Methods / Case Description Results / Findings • Discussion • Conclusion & Key Messages • Acknowledgments & Disclosures
<p><u>Layout & Design</u></p> <ul style="list-style-type: none"> • Clear, readable font (minimum 24 pt for body text) • Use figures, tables, and images where appropriate • Keep content concise and visually engaging • Avoid excessive text blocks 	

4. Ethical Considerations

- Patient confidentiality must be strictly maintained
- Written informed consent is required for case reports
- Images must be anonymized
- Studies must comply with institutional ethical guidelines

5. Reviews & Awards

- All posters will be **peer-reviewed** by the Scientific Committee
- Selected posters will be considered for:
 - **Best Research Poster Award**
 - **Best Case Report Poster Award**

<p style="text-align: center;"><u>Important Dates</u></p> <ul style="list-style-type: none"> • Abstract Submission Deadline: February 15, 2026 • Notification of Acceptance: March 1, 2026 • Poster Display Date: March 28, 2026
<p style="text-align: center;"><u>Submission Process</u></p> <ul style="list-style-type: none"> • Abstracts must be submitted via email / online portal • Email: rheumavision@gmail.com • Subject line: <i>RheumaVision 2026 - Abstract Submission</i>
<p style="text-align: center;"><u>Certificate</u></p> <ul style="list-style-type: none"> • All accepted abstracts will receive an Official Poster Presentation Certificate

